Author Archives: admin


Stem Cell Clinic > Articles by: admin

Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022

By Global News Feed

NEW YORK, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, announced that the Company achieved alignment with the FDA Division of Neurology 1 (“FDA”) to move forward in myasthenia gravis (“MG”). Immunovant plans to start its Phase 3 study for batoclimab in MG in the first half of calendar year 2022.

Go here to see the original:
Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022

Gritstone Announces Presentations during Three Upcoming Investor Conferences

By Global News Feed

EMERYVILLE, Calif., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that Gritstone management will participate in the following upcoming investor conferences in January.

Read more from the original source:
Gritstone Announces Presentations during Three Upcoming Investor Conferences

Registration Now Open For Tribe Public’s Webinar Event "Addressing The Increasing Demand For Rare Cannabinoids" Featuring InMed’s…

By Global News Feed

Meet with InMed’s CEO Eric A. Adams, Shane Johnson, SVP and General Manager of BayMedica and Chris Meiering, VP of Commercial Operations Meet with InMed’s CEO Eric A. Adams, Shane Johnson, SVP and General Manager of BayMedica and Chris Meiering, VP of Commercial Operations

Read more:
Registration Now Open For Tribe Public’s Webinar Event "Addressing The Increasing Demand For Rare Cannabinoids" Featuring InMed’s...

Repligen Corporation to Present at 40th Annual J.P. Morgan Healthcare Conference

By Global News Feed

WALTHAM, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 40th Annual J.P. Morgan Healthcare conference being held January 10-13.  Tony J. Hunt, President and Chief Executive Officer, will present on Wednesday, January 12, 2022, at 9:45 a.m. EST.

Visit link:
Repligen Corporation to Present at 40th Annual J.P. Morgan Healthcare Conference

Biofrontera Inc. announces reduction of Biofrontera AG shareholding to less than 50% through warrant exercises

By Global News Feed

WOBURN, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced that through the exercise of outstanding warrants the majority ownership of Biofrontera AG was diluted below 50%. Biofrontera AG’s shareholding in Biofrontera Inc. of 8,000,000 shares is unchanged, but now represents approximately 47% of the currently outstanding shares. As a result, Biofrontera Inc. is no longer considered a subsidiary of Biofrontera AG. Biofrontera Inc.’s common stock and warrants are traded on the Nasdaq Capital Market under the ticker symbols “BFRI” and “BFRIW,” respectively.

View post:
Biofrontera Inc. announces reduction of Biofrontera AG shareholding to less than 50% through warrant exercises

Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data From COVAXIN™ (BBV152), COVID-19 Candidate Vaccine, in Children 2…

By Global News Feed

MALVERN, Pa., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced today that its partner, Bharat Biotech, posted results from a Phase 2/3 trial conducted in India of candidate vaccine, COVAXIN™ (BBV152), in children, aged 2 – 18 years, demonstrating a robust neutralizing antibody response and favorable safety profile on the pre-print server, medRXiv. Using a two-dose regimen administered 28-days apart, antibody responses in subjects were comparable to adult data from a previous phase 3 study. Those results demonstrated a greater than 93% reduction in severe disease. These pediatric data were the basis of Ocugen’s pediatric Emergency Use Authorization (EUA) submission in the United States for children 2-18 on November 5, 2021.

See more here:
Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data From COVAXIN™ (BBV152), COVID-19 Candidate Vaccine, in Children 2...

→←